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doi:10.1016/j.jmii.2011.09.020Background and Purpose: To investigate the clinical and molecular epidemiology of the
imipenem-resistant Acinetobacter calcoaceticuseAcinetobacter baumannii (IRAcb) complex
during an outbreak in an intensive care unit (ICU).
Methods: Forty-six clinical and 11 environmental isolates of the IRAcb complex were collected
from the ICU of Taipei Veterans General Hospital, Taiwan between December 2003 and March
2004. These isolates were genotyped using pulsed-field gel electrophoresis (PFGE). Carbapene-
mase genes and their associated genetic structures were analyzed using PCR. Clinical data ob-
tained from the patients were also reviewed and analyzed.
Results: The isolateswere identifiedat the genomic species level asA. baumannii (42 clinical and
five environmental isolates) and Acinetobacter genomic species 13TU (four clinical and six envi-
ronmental isolates). Both species were comprised of two pulsotypes, but those of A. baumannii
were closely related (83% similar). IS1008-DISAba3-blaOXA-58-like and ISAba1-blaOXA-51-like were
identified in 22 and 21 clinical isolates of A. baumannii, respectively (one isolate contained
both). The ISAba3-bracketed blaOXA-58-like gene was detected in all isolates of Acinetobacter
genomic species 13TU. Patient transfers between different sections of the ICU were important
factors that contributed to the spread of the two pulsotypes of A. baumannii. However, among
the A. baumannii isolates identified, only those carrying IS1008-DISAba3-blaOXA-58-like could befectious Diseases, Department of Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai
.tw (T.-L. Chen).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
44 Y.-T. Lee et al.found in the environment, indicating an additional route of transmission. The prior use of carba-
penemor cefepimewas associatedwith the subsequent infectionwithA. baumannii carrying the
ISAba1-blaOXA-51-like gene, while prior piperacillin/tazobactam use was associated with the
subsequent infection with A. baumannii carrying the IS1008-DISAba3-blaOXA-58-like gene.
Conclusion: A. baumannii isolates carrying different carbapenemase genes and their associated
genetic structures might be transmitted or selected in different ways.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Members of the genus Acinetobacter, particularly Acineto-
bacter baumannii, Acinetobacter genomic species 13TU,
and Acinetobacter genomic species 3, are important
opportunistic pathogens that are responsible for a variety
of nosocomial infections, especially among critically ill
patients in intensive care units (ICUs).1,2 However, these
species cannot be differentiated by commercial identifi-
cation methods and are, therefore, grouped into the so-
called Acinetobacter calcoaceticuseA. baumannii (Acb)
complex.1 Most outbreaks are caused by A. baumannii,
although A. genomic species 13TU and A. genomic species 3
have also been responsible for several outbreaks.3,4 A more
complicated situation is that, at times, more than one
species can be found within the same period of time,5,6 and
different clones belonging to a single species can be
responsible for the same outbreak.7,8 Therefore, the iden-
tification of the genomic species and the application of
molecular epidemiological methods are warranted in order
to delineate the actual situation of an outbreak caused by
the Acb complex.
The recently observed increase in carbapenem-resistant
Acinetobacter strains has been almost exclusively associated
with hospital outbreaks.9 Among A. baumannii isolates, the
overproduction of carbapenem hydrolyzing class D beta-
lactamases (CHDLs), including those belonging to the OXA-
23, -24, -51, and -58 families, are the most prevalent mech-
anisms for carbapenemresistance.10,11 Theoverexpression of
these CHDL genes are frequently driven by a strong promoter
provided by an upstream insertion sequences.12e15 For
isolates of non-baumannii Acinetobacter spp., the produc-
tion of metallo-beta-lactamases, and sometimes CHDLs, are
usually responsible for carbapenem resistance.2,16,17
An increase in the number of cases with the imipenem-
resistant Acb (IRAcb) complex was observed between
December 2003 and March 2004 in the ICU of Taipei
Veterans General Hospital. The aim of this study is to
characterize the epidemiology of this outbreak in detail by
determining the genomic species of the outbreak strains,
their clonalities, the presence of any carbapenemase gene-
associated genetic structures, and by investigating the
patients’ clinical features and epidemiological data.
Methods
Hospital setting and bacterial strains
Taipei Veterans General Hospital is a 2900-bed tertiary-care
teaching hospital located in Taipei, Taiwan. This hospitalhas its own medical-surgical ICU. The ICU is divided into
three sectionsdA, B and Cdwhich are located side-by-side
and connected by two corridors. Each section has 14 beds
and is run by its own independent nursing staff. Beds in
sections A and B include private rooms that are reserved for
medical and surgical patients, respectively. All of the beds
in section C are located in a single large room, providing
care for both medical and surgical patients. As a conse-
quence, the physicians and surgeons move between
sections A/C and section B/C, respectively. Respiratory
therapists are shuttled between all three sections. During
the study period, patients were transferred to section C
from section A or B when their conditions stabilized, and
transferred from section C to B or A for the purpose of
isolation if culturing detected imipenem-resistant, gram-
negative bacilli or vancomycin-resistant enterococci.
Once it was determined that an outbreak was occurring,
we sought to characterize the molecular epidemiology of
the outbreak by screening all of the patients in the ICU for
IRAcb colonization upon admission and twice weekly
thereafter. The screened specimens included sputum,
intravascular catheter tips, surgical wounds, urine, and
other significant clinical samples; these samples were ob-
tained from each patient in the ICU from December 29,
2003 through March 22, 2004. We also obtained environ-
mental samples after the first three case patients were
identified by swabbing the objects in the environment and
equipment adjacent to the patients in sections A, B, and C
(including the headboard, bed rails, door handles, and
external surfaces of the intravenous pump machines,
ventilators, and monitors), as well as by culturing samples
from the hands of 70 hospital care workers (doctors, nurses,
and respiratory therapists) over the first three consecutive
days after the first three case patients were identified, as
previously described.18 The presumptive identification of
any isolates was obtained using the API ID 32 GN system
(bioMe´rieux, Marcy l’Etoile, France).Definitions
Nosocomial infection was defined based on the definition of
nosocomial infection provided by the Centers for Disease
Control and Prevention.19 Colonization was defined as the
isolation of an Acb complex isolate from at least one clin-
ical specimen in the absence of the clinical symptoms
consistent with infection. Case patients were defined as
those in the ICU with infection or those identified as
carrying the IRAcb complex during the study period. Acute
renal failure was defined as a serum creatinine value of
2 mg/dL, a 50% reduction in creatinine clearance, or as
Table 1 Primers used in this study
Primer Target Sequence (50to 30)
rA1 recA CCTGAATCTTCTGGTAAAAC
rA2 GTTTCTGGGCTGCCAAACATTAC
Ab-ITSF internal fragment
of 16S-23S rRNA
intergenic
spacer region
CATTATCACGGTAATTAGTG
Ab-ITSB AGAGCACTGTGCACTTAAG
ISAba1F ISAba1 CACGAATGCAGAAGTTG
ISAba1R CGACGAATACTATGACAC
ISAba2A tnpA of ISAba2 AATCCGAGATAGAGCGGTTC
ISAba2B TGACACATAACCTAGTGCAC
ISAba3A tnpA of ISAba3 CAATCAAATGTCCAACCTGC
ISAba3B CGTTTACCCCAAACATAAGC
ISAba4A tnpA of ISAba4 ATTTGAACCCATCTATTGGC
ISAba4B ACTCTCATATTTTTTCTT
IS18A tnpA of IS18 CACCCAACTTTCTCAAGATG
IS18B ACCAGCCATAACTTCACTCG
IS1008F tnpA of IS1008 TCTAGATCGGCACTTTCAAGGT
GAAAT
m23F blaOXA-23-like GATCGGATTGGAGAACCAGA
m23R ATTTCTGACCGCATTTCCAT
m24F blaOXA-24-like GGTTAGTTGGCCCCCTTAAA
m24R AGTTGAGCGAAAAGGGGATT
m51F blaOXA-51-like TAATGCTTTGATCGGCCTTG
m51R TGGATTGCACTTCATCTTGG
m58F blaOXA-58-like CCCCTCTGCGCTCTACATAC
m58R AAGTATTGGGGCTTGTGCTG
IMP-F blaIMP-like GGAATAGRGTGGCTTAAYTCTC
IMP-R TGGCCAAGCTTCWAHATTTGC
VIM1-F blaVIM-1,4,5,13,14 GGTTGTATACGTCCCGTCAG
VIM1-R TGCTTTGACAACGTTCGC
VIM2-F blaVIM-2,3,6,8,9,10,11 CTATCATGGCTATTGCGAG
VIM2-R ATCGCACAACCACCATAG
SIM1-F blaSIM-1 TACAAGGGATTCGGCATCG
SIM1-R TAATGCTCCTGTTCCCATGTG
SPM1-F blaSPM-1 AGACCGCGATTTCTATTCTT
SPM1-R AGTTCCTTCGGCTTTATCAT
GIM1-R blaGIM-1 AGAACCTTGACCGAACGCAG
GIM1-F ACTCATGACTCCTCACGAGG
Outbreak of imipenem-resistant Acinetobacter baumannii 45a decline in renal function that prompted the initiation of
renal replacement therapy.
Data collection
Patient medical records were reviewed in order to extract
epidemiologic data and clinical information, including age,
gender, durations of ICU and hospital stays, sites of infec-
tion or colonization, time from admission to acquisition,
underlying diseases, reasons for ICU admission, date and
type of antimicrobial therapy received, mechanical venti-
lation required, and clinical outcome. The severity of each
patient’s illness was evaluated using the acute physiology
and chronic health evaluation II (APACHE II) score20 and the
sequential organ failure assessment (SOFA) score21; these
scores were recorded at the time of admission to the ICU
and at the first time of IRAcb isolation from each patient
during the study period. All of the procedures used were in
accordance with the recommendations found in the Hel-
sinki Declaration of 1975. Guidelines for human experi-
mentation and the appropriate conduct for clinical
research were followed, as required by the institutional
review board of Taipei Veterans General Hospital.
Species identification and antimicrobial
susceptibilities
The identification of A. baumannii was performed using the
multiplex-PCR method with two pairs of primers: 1) Ab-ITSF
and Ab-ITSB and 2) rA1 and rA2 (Table 1).22 Other isolates
identified as other Acinetobacter species were identified at
the genomic species level using 16S-23S ribosomal DNA
intergenic spacer (ITS) sequence analysis.23 The minimum
inhibitory concentrations (MICs) for tigecycline and colistin
were determined using the E-test (AB BIODISK, Solna,
Sweden) or agar dilution with colistin sulfate (Sigma
Aldrich, St. Louis, MO, USA), respectively. All other MICs
were determined by broth dilution using the automated
Sensititre Susceptibility Plate (TREK Diagnostic Systems
Ltd., West Sussex, UK). The results were interpreted
according to the guidelines of the Clinical Laboratory
Standards Institute (CLSI),24 except for tigecycline’s
breakpoints which were interpreted according to the
criteria of the U.S. Food and Drug Administration (suscep-
tibility is defined as 2 mg/mL; resistance as 8 mg/mL).
Molecular typing
The clonal relationships of the IRAcb isolates were deter-
mined by pulsed-field gel electrophoresis (PFGE). PFGE of
ApaI-digested genomic DNA was performed using the Bio-
Rad CHEF-Mapper apparatus (Bio-Rad Laboratories,
Hercules, CA, USA). DNA restriction patterns were inter-
preted according to the criteria of Tenover et al25 and
cluster analysis was performed using GelCompar II v. 3.5
(Applied Maths, Sint-Martens-Latem, Belgium) and the
unweighted pair-group method with arithmetic averages
(UPGMA). The Dice correlation coefficient was used with
a tolerance of 1% in order to analyze any similarities
between banding patterns. In brief, isolates showing more
than three DNA fragment differences and a similarity of<85% following dendrogram analysis were considered to
represent different PFGE types.
Detection of CHDLs, MBLs, and genes upstream
of CHDL
Detection of the CHDL genes (blaOXA-23-like, blaOXA-24-like,
blaOXA-51-like, and blaOXA-58-like) was performed using
a multiplex PCR assay.26 The upstream locations of the
insertion sequences (ISs) were mapped by PCR using
forward primers within the ISs and reverse primers within
the carbapenemase genes (Table 1).13,27,28 MBLs were
detected by phenotypic tests and PCR assays. MBL pheno-
typic detection used the imipenem and imipenem-EDTA
combined-disk test and the imipenem and EDTA-sodium
mercaptoacetic acid (SMA) double-disk synergy test, as
previously described.17 PCR analysis was used to confirm
the presence of MBL genes with primers specific to
46 Y.-T. Lee et al.the blaIMP, blaVIM, blaSIM, blaSPM and blaGIM-1 genes
(Table 1).29e32
Statistical analysis
The Chi-square tests with Yates’ correction or Fisher’s
exact test were used to compare discrete variables.
Fisher’s exact test was used instead of the Chi-square test
with Yates’ correction when one or more expected values in
the 2  2 contingency table were less than 5. The
comparison of two quantitative variables was made using
the Mann-Whitney test for nonparametric variables and the
Student t test for parametric variables. Two-sided tests
were used for all analyses. A p-value <0.05 was considered
statistically significant. All analyses were performed using
the Statistical Package for the Social Sciences (SPSS)
version 15.0 (SPSS, Chicago, IL, USA).
Results
Clinical characteristics of case patients
During the study period, 27 ICU patients became infected
(17 patients) or colonized (10 patients) with IRAcb. The
infected/colonized patients represented approximately
16.6% (27/163) of the total population of ICU patients
admitted during the outbreak. No patient was found to be
positive for IRAcb before ICU admission or on their first
screening upon admission to the ICU. The main reasons for
ICU admission were pneumonia and postsurgical complica-
tions. All patients were mechanically ventilated. The sites
of infection included the respiratory tract (nZ 12), wound
sites (nZ 4), and urinary tract (nZ 1). Three patients had
concomitant bacteremia. Of the infected and colonized
patients, 12 and four patients died, respectively. No
statistical significance was observed between infected and
colonized patients in terms of the all-cause mortality
(70.6% vs. 40.0%, p Z 0.224).
Species identification and antimicrobial
susceptibilities
During the study period, 46 isolates of IRAcb were recov-
ered from one or more clinical samples that were obtained
from the case patients. Forty-two isolates were identified
as A. baumannii and the other four isolates were recog-
nized as Acinetobacter genomic species 13TU. Analysis of
72 samples obtained from the patients’ direct environ-
ment, including equipment, yielded four imipenem-
resistant A. baumannii isolates (from the bed head-
boards, support stands of the infusion pump, pulseoxy-
meters, and ventilation hoses) and five imipenem-
resistant isolates of Acinetobacter genomic species 13TU
(from the door handles, curtains, surfaces of the venti-
lator, water taps, and procedure trolleys). In addition, one
isolate of A. baumannii and one isolate Acinetobacter
genomic species 13TU were recovered from cultures of
samples obtained from the hands of 70 hospital care
workers (from one surgeon and one respiratory therapist,
respectively).Imipenem MICs of the isolates ranged between 16 and 64
mg/mL. All of the study isolates were resistant to piper-
acillin/tazobactam. All of the A. baumannii isolates were
resistant to ceftazidime, cefepime, ampicillin/sulbactam,
and ciprofloxacin, for which two, one, one, and all 10 of the
isolates from Acinetobacter genomic species 13TU,
respectively, were defined as susceptible. All but four
clinical isolates of A. baumannii showed resistance to all
three aminoglycosides tested (gentamicin, amikacin, and
tobramycin). The four aminoglycoside susceptible isolates
were all from the same pulsotype: pulsotype B.
Molecular epidemiology and distributions of
carbapenemase gene-associated genetic structures
The clinical isolates of A. baumannii identified in this study
were grouped into two pulsotypes, designated pulsotypes A
and B, all which were relatively similar (83%). All environ-
mental isolates of A. baumannii belonged to pulsotype B.
The clinical isolates of Acinetobacter genomic species 13TU
were classified as pulsotypes C and D (each pulsotype
included two isolates). All of the environmental isolates of
A. baumannii and Acinetobacter genomic species 13TU
belonged to pulsotype B and D, respectively. All of the
environmental IRAcb isolates, except one, were obtained in
proximity to the patient with the same strain or from the
hands of a hospital care worker who cared for the patient
with the same strain. The PFGE results of half of the clinical
isolates belonging to the four different pulsotypes and one
representative strain of environmental isolates belonging to
each species are shown in Fig. 1.
The blaOXA-58-like gene was detected in 22 clinical isolates
of imipenem-resistant A. baumannii (all belonging to pul-
sotype B), in all of the four clinical isolates of Acineto-
bacter genomic species 13TU (pulsotypes C and D), and in
all 11 of the environmental isolates of IRAcb. All of the
blaOXA-58-like genes found in A. baumannii had an upstream
insertions of the truncated ISAba3 and IS1008 versions of
this gene (IS1008-DISAba3-blaOXA-58-like),
27 while ISAba3 was
found both upstream and downstream of the blaOXA-58-like
gene in all isolates of Acinetobacter genomic species
13TU. In one of the A. baumannii isolates carrying
IS1008-DISAba3-blaOXA-58-like and 20 clinical isolates of
A. baumannii without blaOXA-58-like gene (belonging to
either pulsotype A or B), ISAba1 was found upstream of
blaOXA-51-like. BlaOXA-23-like, blaOXA-24-like genes, and MBL
geneswere not detected in any isolate identified in this study.
Phenotypic assays also failed to identify MBL production.
Different isolates collected from the same patient had
identical pulsotypes and carried the same carbapenemase
gene-associated genetic structures, except in two patients
(patient No. 9 and No. 19; Fig. 2), for which additional
details are provided below.
Outbreak investigation
A timeline was constructed to follow the occurrence of new
cases in relation to patient movements and locations
(Fig. 2). The first isolate carrying IS1008-DISAba3-blaOXA-58-like
was identified in patient No. 4 in section C, but the origin
of A. baumannii could not be traced. The emergence of
Figure 1. Pulsed-field gel electrophoresis profiles, genomic species identification, isolation locations, and carbapenemase genes
of representative clinical and environmental strains in this study. i-e01, a representative environmental strain of Acinetobacter
genomic species 13TU; i-e03, a representative environmental strain of A. baumannii; A. b, Acinetobacter baumannii; 13TU, Aci-
netobacter genomic species 13TU.
Outbreak of imipenem-resistant Acinetobacter baumannii 47isolates with IS1008-DISAba3-blaOXA-58-like in section B
could be traced to the transfer of patient No. 4, but no
patient transfer could account for the appearance of
isolates with IS1008-DISAba3-blaOXA-58-like in section A
(patient No. 10).
An isolate with ISAba1-blaOXA-51-like was first identified
in a female patient (case No. 15) in section A. This patient
had been previously colonized with multidrug-resistant
(but not imipenem-resistant) A. baumannii for 2 months
and was transferred to the ICU from a local hospital upon
admission. Then, imipenem-resistant A. baumannii with
ISAba1-blaOXA-51-like appeared in section C after patient
No.16 was transferred from section A to section C. Simi-
larly, an isolate with ISAba1-blaOXA-51-like was identified in
section B (patient No. 21) after patient No. 20 was moved
from section A to section B.
In patient No. 9, the first two imipenem-resistant A.
baumannii isolates (i-013 and i-014) were identified,
which were collected on the same day, and these isolates
carried different carbapenemase genes (i-013 carried
IS1008-DISAba3-blaOXA-58-like and i-014 contained both
ISAba1-blaOXA-51-like and IS1008-DISAba3-blaOXA-58-like),
although they exhibited identical pulsotypes (Fig. 1). Around
the time when i-014 was identified in patient No. 9 in section
C, clusters of isolates with either ISAba1-blaOXA-51-like or
IS1008-DISAba3-blaOXA-58-like were noted in section C.
In patient No. 19, an isolate harboring ISAba1-blaOXA-51-like
was initially isolated in section C (i-010). Fourteen days after
patient No. 19was transferred from section A to section B, anisolate carrying IS1008-DISAba3- blaOXA-58-like (i-021) was
discovered. These two isolates belonged to different pulso-
types. Just before i-021 was identified, isolates with IS1008-
DISAba3- blaOXA-58-like were discovered in three patients in
section B in the vicinity of patient No. 19. However, patient
No. 19 might also have been colonized/infected during his
short stay in section C (i002, i003, and i013).Comparisons of patients whose first imipenem-
resistant A. baumannii isolate carried different
carbapenemase gene-associated genetic structures
Patients whose first imipenem-resistant A. baumannii
isolate carried ISAba1-blaOXA-51-like or IS1008-DISAba3-
blaOXA-58-like are compared in Table 2. Patient No. 9 was
excluded because one of his first two imipenem-resistant
A. baumannii isolates simultaneously harbored two types
of genetic structures. No significant differences were
observed between the two patient groups in terms of age,
underlying diseases, clinical presentations, disease
severity, mortality, mechanical ventilation, or the lengths
of their respective hospital stays. Compared to the patients
whose first imipenem-resistant A. baumannii isolate carried
IS1008-DISAba3-blaOXA-58-like, those whose isolates carried
ISAba1-blaOXA-51-like tended to have been treated with car-
bapenems or cefepime. Prior treatment with piperacillin/
tazobactam, however, was observed more frequently in the
patients whose first imipenem-resistant A. baumannii
Figure 2. Timeline of the colonization or infection of the 27 patients with imipenem-resistant A. baumannii or Acinetobacter
genomic 13TU who were identified during the outbreak. - Date of the first imipenem-resistant A. baumannii isolate with
ISAba1-blaOXA-51-like.C Date of the first imipenem-resistant isolate of Acinetobacter genomic species 13TU with ISAba3-bracketed
blaOXA-58-like.: Date of the first imipenem-resistant A. baumannii isolate with IS1008-DISAba3-blaOXA-58-like.; Date of the first
imipenem-resistant A. baumannii isolate from patient No. 9 with both ISAba1-blaOXA-51-like and IS1008-DISAba3-blaOXA-58-like.
a For
patient No. 9, the first two imipenem-resistant A. baumannii isolates were collected on the same day.
48 Y.-T. Lee et al.isolate carried IS1008-DISAba3-blaOXA-58-like. When confined
to just those patients whose first imipenem-resistant A.
baumannii isolate belonged to pulsotype B, there were no
significant differences regarding any of the above-
mentioned parameters between the two patient groups
whose first imipenem-resistant A. baumannii isolate carried
IS1008-DISAba3-blaOXA-58-like and ISAba1-blaOXA-51-like,
respectively. During the outbreak period, no preferences in
the use of certain antimicrobial agents were noted in any
section of the ICU and there were no differences in anti-
microbial agents used among the three sections.
Infection control measures
Infection control measures were applied to all affected
patients, including isolation in a private room, strict hand
hygiene, and the required use of gowns and gloves before
entering rooms. The minimum number of staff required for
care was allowed to enter each affected room, with medical
staff seeing affected patients last on their rounds around
each ward. Nurses were limited to caring for either affected
or unaffected patients. Movement between the sections was
restricted. The antibiotic policy was not changed because
the controlled administration of prescriptions was routine
practice in the ICU. Potentially contaminated medicalequipment was cleaned and disinfected with disinfectants
using an effective concentration for the provisioned amount
of time. The performance of personnel was closely moni-
tored. No additional cases were found after the last positive
patient left the ICU at the end of April 2004.
Discussion
In this study, different carbapenemase gene-associated
genetic structures were observed among isolates belonging
to the identical pulsotypes. Similar findings have been re-
ported during outbreaks of carbapenem-resistant A. bau-
mannii.8 So-called “micro-variation,” as revealed by PFGE
profiling, coupled with extra information obtained by the
detection of additional genes, is thought to be helpful for
investigating individual outbreaks of A. baumannii.33 A care-
ful review of the intra-ICU movements of our study patients
and the progression of clones revealed that, within a single
clone of A. baumannii, infection or colonization with isolates
carrying different genetic structures followed different
epidemiologic patterns of hospital acquisition andpatient-to-
patient transmission. Our findings further emphasize that
PFGE and the detection of carbapenemase gene-associated
genetic structures are warranted when investigating an
outbreak caused by carbapenem-resistant acinetobacters.
Table 2 Comparisons of patients whose first imipenem-resistant Acinetoabacter baumannii isolate carried ISAba1-blaOXA-51-like
and patients whose first imipenem-resistant A. baumannii isolate carried IS1008-DISAba3-blaOXA-58-like
Patients whose first imipenem-
resistant A. baumannii isolate
carried ISAba1-blaOXA-51-like
(n Z 13)
Patients whose first imipenem-
resistant A. baumannii isolate
carried IS1008-DISAba3-blaOXA-58-like
(n Z 10)
p-value
n % Mean  SD n % Mean  SD
Age (y) 69.1  14.4 60.9  18.1 0.263
APACHE II score upon ICU admission 32.6  9.4 29.6  6.3 0.248
SOFA score upon ICU admission 15.0  10.7 15.0  9.6 0.333
APACHE II score at culture date a 33.2  9.8 28.7  7.2 0.305
SOFA score at culture date a 10.3  5.4 7.9  3.4 0.349
Length of hospital stay (d) 60.2  29.7 86.0  39.6 0.088
Length of ICU stay (d) 32.2  15.5 51.2  25.6 0.051
Admission to culture date (d) 25.5  21.8 23.2  15.0 0.964
ICU admission to culture date (d) 10.0  8.9 15.2  10.3 0.151
Length of mechanical ventilation (d) 33.5  24.8 54.8  36.1 0.171
Transfer from other hospital b 5 38.5 2 20.0 0.405
Mortality 9 69.2 5 50.0 0.417
Presentation
Infection 7 53.8 6 60.0 1.000
Colonization 6 46.2 4 40.0 1.000
Hypotension or shock c 9 69.2 4 40.0 0.222
Acute renal failure 9 69.2 5 50.0 0.417
Underlying disease
Diabetes mellitus 4 30.8 5 50.0 0.417
Chronic pulmonary disease 3 23.1 0 0.0 0.604
Malignancy 4 30.8 4 40.0 0.685
First isolate discovered at
Section A/B/C 5/2/6 2/5/3 0.323
Previous use of d
Carbapeneme 6 46.2 0 0 0.019
Cefepimef 5 38.5 0 0 0.046
Piperacillin/tazobactamg 1 7.7 6 60.0 0.019
Ciprofloxacin 4 30.8 5 50.0 0.417
Teicoplanin 7 53.8 7 70.0 0.669
a Time at which the first isolate of imipenem-resistant A. baumannii was collected from each case patient.
b Patient had been hospitalized in another hospital and then transferred to our emergency room just prior to admission.
c Occurred in the 48-hour period around the time of the first isolate of imipenem-resistant A. baumannii was collected.
d One of the antibiotics as listed below (carbapenem, cefepime, piperacillin/tazobactam, ciprofloxacin or teicoplanin) has been used
within 30 days before the first imipenem-resistant A. baumannii isolate was discovered and the antibiotic has been used for at least 72
hours.
e Carbapenem included imipenem and meropenem. The duration of carbapenem therapy in these six patients ranged from 4e11 days
(average 7.2).
f The duration of cefepime therapy in these five patients ranged from 4e12 days (average 6.8).
g The duration of piperacillin/tazobactam therapy in the patient whose first imipenem-resistant A. baumannii isolate carried
ISAba1-blaOXA-51-like was 10 days and the duration of piperacillin/tazobactam therapy in the 6 patients whose first imipenem-resistant
A. baumannii isolate carried IS1008-DISAba3-blaOXA-58-like were 5e23 days (average 14.2).
Outbreak of imipenem-resistant Acinetobacter baumannii 49According to the timeline, following the occurrence of
new cases in relation to patient movements and locations,
patient transfer between ICU sections was suggested as one
of the reasons for the rapid progression of the clones within
the three ICU sections. Patient-to-patient transmission via
patient transfer explains most cases of transmission, espe-
cially for imipenem-resistant A. baumannii isolates with
ISAba1-blaOXA-51-like. Environmental contamination may
also have played a role in disseminating the outbreak
strains. Interestingly, IS1008-DISAba3-blaOXA-58-like, but not
ISAba1-blaOXA-51-like, was detected in all of theenvironmental isolates of A. baumannii. A possible expla-
nation is that the common source of the isolates with
ISAba1-blaOXA-51-like was not derived from the environment,
or that there may be differences in the abilities of isolates
with IS1008-DISAba3-blaOXA-58-like and ISAba1-blaOXA-51-like
to survive in an inanimate environment. The high preva-
lence of IS1008-DISAba3-blaOXA-58-like and ISAba3-bracketed
blaOXA-58-like genes in environmental isolates of A. baumannii
and Acinetobacter genomic species 13TU, respectively, also
suggest that environmental contamination may explain the
transmission of isolates with IS1008-DISAba3-blaOXA-58-like to
50 Y.-T. Lee et al.section A, and this may be the main mode of transmission for
isolates of Acinetobacter genomic species 13TUwith ISAba3-
bracketed blaOXA-58-like gene.
It has been reported that the use of carbapenemor certain
classes of antibiotics is associated with the subsequent
evolution of multidrug-resistant or extensive drug-resistant
A. baumannii.34,35 To the best of our knowledge, this is the
first report to identify the correlation between the use of
different antimicrobial agents and the subsequent acquisi-
tion of imipenem-resistant A. baumannii isolates that carry
different carbapenemase gene-associated genetic struc-
tures. Although only a small number of patients were
included, statistical significance was detected. In a recent
study, introducing ISAba1-blaOXA-51-like failed to transform
piperacillin/tazobactam-susceptible A. baumannii to
a piperacillin/tazobactam-resistant strain,36 indicating that
ISAba1-blaOXA-51-like does not confer resistance to piper-
acillin/tazobactam and that isolates carrying only this
genetic structure may succumb to piperacillin/tazobactam.
It has also been shown that the overexpression of the
blaOXA-58 gene contributes to resistance to piperacillin/
tazobactam.37 It remains to be seen if the acquisition of
different carbapenemase genes in A. baumannii can be
determined by using different antimicrobial agents.
The genetic structure IS1008-DISAba3-blaOXA-58-like was
first reported by one of our team members in a study on one
of the A. baumannii strains identified during this outbreak.
This structure was identified in a plasmid, and acquisition
of this plasmid-borne genetic structure conferred a high
level of carbapenem resistance to A. baumannii.27 ISAba1-
blaOXA-51-like also appeared to be involved in the carbape-
nem resistance of A. baumannii.28,36 However, what the
actual mechanism of carbapenem resistance is in our Aci-
netobacter genomic species 13TU remains in doubt. The
ISAba3-bracketed blaOXA-58-like gene alone is not sufficient
to provide a high degree of carbapenem resistance in
A. baumannii,38 and this genetic structure has been iden-
tified in a plasmid of a clinical isolate of Acinetobacter
genomic species 13TU for which the imipenem MIC was 6
mg/mL.39 Furthermore, no known MBL genes were detected
in our isolates by PCR or phenotypic assays. It is still under
investigation whether there may be other carbapenemase-
independent mechanisms involved.
In conclusion, epidemiologic clarification of an outbreak
caused by carbapenem-resistant Acinetobacter species
required not only genomic species identification and PFGE
analysis but also the detection of carbapenemase gene-
associated genetic structures. Patient transfers between
wardsandenvironmental contaminationmight playdifferent
roles in the transmission of the closely related A. baumannii
pulsotypes that harbor different carbapenemase-associated
genetic structures. It remains to be investigatedwhether the
isolates that carrydifferent carbapenemase gene-associated
genetic structures differ based on their abilities to survive in
the environment or if they can be selected using different
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